Advanced search
1 file | 519.03 KB

Caniene cutane mastceltumoren

Lynn Van Eetvelde (UGent) , Koen Chiers (UGent) and Leen Van Brantegem (UGent)
Author
Organization
Abstract
Canine cutaneous mast cell tumors (cMCT) are a commonly encountered neoplasia in small animal practice. Ninety-six percent of the cMCT can be diagnosed with cytology. Because of the variating biological character, it's difficult to establish a prognosis. Therefore, the prognosis is assessed with multiple prognostic factors: tumor location, systemic complaints, metastases, histological and cytological grading, proliferation markers, KIT-staining pattern, KIT-mutation and tumor free margins. The treatment of choice is based upon the results of these prognostic factors, the clinical stage and the tumor location. Possible treatments include surgery, radiotherapy, chemotherapy, electrochemotherapy, tyrosine kinase inhibitors, cryotherapy and intraregional therapy with deionized water.
Keywords
PROGNOSTIC-FACTORS, SURGICAL EXCISION, DOUBLE-BLIND, DOGS, SURVIVAL, THERAPY, MASTOCYTOSIS, PREDNISONE, EXPRESSION, BEHAVIOR

Downloads

  • Dutchart06.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 519.03 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Van Eetvelde, Lynn, Koen Chiers, and Leen Van Brantegem. 2017. “Caniene Cutane Mastceltumoren.” Vlaams Diergeneeskundig Tijdschrift 86 (5): 311–321.
APA
Van Eetvelde, L., Chiers, K., & Van Brantegem, L. (2017). Caniene cutane mastceltumoren. VLAAMS DIERGENEESKUNDIG TIJDSCHRIFT, 86(5), 311–321.
Vancouver
1.
Van Eetvelde L, Chiers K, Van Brantegem L. Caniene cutane mastceltumoren. VLAAMS DIERGENEESKUNDIG TIJDSCHRIFT. 2017;86(5):311–21.
MLA
Van Eetvelde, Lynn, Koen Chiers, and Leen Van Brantegem. “Caniene Cutane Mastceltumoren.” VLAAMS DIERGENEESKUNDIG TIJDSCHRIFT 86.5 (2017): 311–321. Print.
@article{8549390,
  abstract     = {Canine cutaneous mast cell tumors (cMCT) are a commonly encountered neoplasia in small animal practice. Ninety-six percent of the cMCT can be diagnosed with cytology. Because of the variating biological character, it's difficult to establish a prognosis. Therefore, the prognosis is assessed with multiple prognostic factors: tumor location, systemic complaints, metastases, histological and cytological grading, proliferation markers, KIT-staining pattern, KIT-mutation and tumor free margins. The treatment of choice is based upon the results of these prognostic factors, the clinical stage and the tumor location. Possible treatments include surgery, radiotherapy, chemotherapy, electrochemotherapy, tyrosine kinase inhibitors, cryotherapy and intraregional therapy with deionized water.},
  author       = {Van Eetvelde, Lynn and Chiers, Koen and Van Brantegem, Leen},
  issn         = {0303-9021},
  journal      = {VLAAMS DIERGENEESKUNDIG TIJDSCHRIFT},
  keyword      = {PROGNOSTIC-FACTORS,SURGICAL EXCISION,DOUBLE-BLIND,DOGS,SURVIVAL,THERAPY,MASTOCYTOSIS,PREDNISONE,EXPRESSION,BEHAVIOR},
  language     = {dut},
  number       = {5},
  pages        = {311--321},
  title        = {Caniene cutane mastceltumoren},
  volume       = {86},
  year         = {2017},
}

Web of Science
Times cited: